Oramed Pharmaceuticals (ORMP) EBITDA Margin (2016 - 2025)

Oramed Pharmaceuticals has reported EBITDA Margin for 8 years, with the latest figure at 225.0% in Q1 2025.

• For the quarter ending Q1 2025, EBITDA Margin changed N/A year-over-year to 225.0%; the trailing twelve-month figure through Dec 2025 stood at 790.9% (changed N/A YoY), and the FY2025 full-year result was 790.9%, changed N/A from the prior year.
• EBITDA Margin for Q1 2025 stood at 225.0%, up from 562.46% in the prior quarter.
• The five-year high for EBITDA Margin was 225.0% in Q1 2025, with the low at 1693.92% in Q2 2022.
• Historically, EBITDA Margin has averaged 1051.65% across 4 years, with a median of 1048.44% in 2021.
• The largest YoY upside for EBITDA Margin was 113145 bps in 2023 against a maximum downside of 90751 bps in 2023.
• Oramed Pharmaceuticals' EBITDA Margin stood at 896.15% in 2021, then slumped by 52 bps to 1363.5% in 2022, then soared by 59 bps to 562.46% in 2023, then soared by 60 bps to 225.0% in 2025.
• The last three EBITDA Margin figures came in at 225.0% (Q1 2025), 562.46% (Q2 2023), and 781.98% (Q1 2023), per Business Quant data.